The U.S. Food and Drug Administration granted accelerated approval of Janssen’s Rybrevant (amivantamab-vmjw) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.

Tagrisso

AstraZeneca Plc said on April 14 that China’s health regulator expanded the use of Tagrisso, the British drugmaker’s lung cancer treatment, in patients with a type of lung cancer when diagnosed at an early stage.

AstraZeneca Plc said a late-stage study showed the company’s top-selling drug Tagrisso had significantly helped patients with a type of lung cancer live longer without the disease worsening.

There was a flurry of activity during the first few days of the American Society of Clinical Oncology, with multiple presentations made showing the benefits of various oncology treatments.

AbbVie halted the Phase III INTELLANCE-1 trial of depatuxizumab mafodotin in patients with newly diagnosed glioblastoma whose tumors have epidermal growth factor receptor amplification.

AstraZeneca today announced that the US Food and Drug Administration granted Breakthrough Therapy Designation for Tagrisso (osimertinib) for the first-line treatment of patients with metastatic epidermal growth factor receptor mutation-positive non-small cell lung cancer.